

Information provided under RTI Act. 2005 in – 2020-22

REGIONAL DRUGS TESTING LABORATORY, CENTRAL DRUGS STANDARD CONTROL ORGANISATION, (Directorate General of Health services), Ministry of Health & Family Welfare, SECTOR-39C, CHANDIGARH – 160036

➤ **RTI Application No: 1**

Receipt Date: 04.05.2020

Reply date: 12.05.2020

Sl. No.	Information Sought	Reply
5. (i)	Certified Copies of Analysis Report in Form 13 of Drugs or Medicines of the following	
1	<p>Product Name: Hydroxy Propyl Methyl Cellulose Ophthalmic Solution (Hypromellose Ophthalmic Solution USP)</p> <p>Batch No.: 8B05170</p> <p>Mfg Date: 12/2018</p> <p>Expiry Date: 11/2020</p> <p>Manufactured by: M/s. Ciron Drugs & Pharmaceuticals Pvt Ltd.</p>	<ul style="list-style-type: none">This institute is bound by the fiduciary relationship of trust with the senders of the samples (Drugs, Cosmetics and medical devices), i.e. Drugs Inspector and Drugs Officers. Because this office is used to charge the testing fees for samples as per Schedule “B” of Drugs and Cosmetics Act 1940 and Rules 1945 there under. <p>The lists of legal failed samples are regularly being uploaded under the Drug Alert of the CDSCO website, i.e. www.cdSCO.gov.in (Notifications → Alert). One of the most important purposes of this Drug Alert is to provide information or to educate the common people about the drugs, cosmetics and medical devices which are safe and fit for use.</p> <p>So, the information available to a person in his fiduciary relationship of trust cannot be disclosed under section 8 (1) (e) of RTI Act, 2005 where the large public interests is already being served.</p> <ul style="list-style-type: none">Providing the test reports of samples, as demanded by the applicant may incur a large financial loss for this institute, as this institute is used to charge fees for the

		<p>testing of samples as mentioned earlier.</p> <p>So, in this situation it cannot be a wise decision to create an option for a large probable financial loss in future for a Central Government Institute by providing the test reports as are demanded, when the large public interests is already being served.</p>
2	<p>Product Name: Hydroxy Propyl Methyl Cellulose Ophthalmic Solution USP along with Sterile Pricon Angular Cannula 23G. (Appavisc PFS Solution)</p> <p>Batch No.: PFB-701, OPCP-195</p> <p>Mfg Date: 02/2018</p> <p>Expiry Date: 01/2020</p> <p>Manufactured by: M/s. Appasamy Ocular Devices (P) Ltd.</p>	<ul style="list-style-type: none"> As mentioned earlier in the reply of Sl. No. (1).
3	<p>Product Name: Dexamethasone sodium phosphate Injection IP</p> <p>Batch No.: 317-936</p> <p>Mfg Date: 09/2017</p> <p>Expiry Date: 08/2019</p> <p>Manufactured by: M/s. Zee Laboratories Ltd.</p>	<ul style="list-style-type: none"> As mentioned earlier in the reply of Sl. No. (1).

4	<p>Product Name: Heparin Injection IP 25000 Units (Azzirin Injection)</p> <p>Batch No.: MCP19388</p> <p>Mfg Date: 08/2018</p> <p>Expiry Date: 07/2020</p> <p>Manufactured by: M/s. Health Biotech Ltd.</p>	<ul style="list-style-type: none"> As mentioned earlier in the reply of Sl. No. (1).
5	<p>Product Name: Hyaluronidase Injection IP (Ovine) (Hynidase Injection)</p> <p>Batch No.: SA1812059</p> <p>Mfg Date: 06/2018</p> <p>Expiry Date: 05/2021</p> <p>Manufactured by: M/s. Shreya Life Science Pvt Ltd.</p>	<ul style="list-style-type: none"> As mentioned earlier in the reply of Sl. No. (1).
6	<p>Product Name: Hyaluronidase Injection IP (Ovine) (Hynidase Injection)</p> <p>Batch No.: SA1812060</p> <p>Mfg Date: 06/2018</p> <p>Expiry Date:</p>	<ul style="list-style-type: none"> As mentioned earlier in the reply of Sl. No. (1).

05/2021	Manufactured by: M/s. Shreya Life Science Pvt Ltd.
---------	---

➤ **RTI Application No: 2**

Receipt Date: 27.05.2020

Reply date: 02.06.2020

Sl. No.	Information Sought	Reply										
1.	Kindly provide the information about the name and total numbers of drugs tested in the 7 government laboratories from 2016 to 2019 for each year separately.	<ul style="list-style-type: none"> The total number of drugs tested in this laboratory from 2016 to 2019 are given below; <table border="1"> <thead> <tr> <th><u>Year</u></th> <th><u>No. of Drugs Tested</u></th> </tr> </thead> <tbody> <tr> <td>01/01/2016 to 31/12/2016</td> <td>1794</td> </tr> <tr> <td>01/01/2017 to 31/12/2017</td> <td>4682</td> </tr> <tr> <td>01/01/2018 to 31/12/2018</td> <td>3561</td> </tr> <tr> <td>01/01/2019 to 31/12/2019</td> <td>3073</td> </tr> </tbody> </table> The list for the names of the above said total drugs is found to contain 1207 pages. Making copies of such huge amount of information will be a daunting task and this will disproportionately divert the resources of this institute and hence information is denied u/s 7 (9) of RTI Act, 2005. It is requested to the Appellant that if you have specific queries for a particular sample, may submit your specific and suitable queries, so that you will be provided with your desired information, if available. 	<u>Year</u>	<u>No. of Drugs Tested</u>	01/01/2016 to 31/12/2016	1794	01/01/2017 to 31/12/2017	4682	01/01/2018 to 31/12/2018	3561	01/01/2019 to 31/12/2019	3073
<u>Year</u>	<u>No. of Drugs Tested</u>											
01/01/2016 to 31/12/2016	1794											
01/01/2017 to 31/12/2017	4682											
01/01/2018 to 31/12/2018	3561											
01/01/2019 to 31/12/2019	3073											

➤ **RTI Application No: 3**

Receipt Date: 15.09.2020

Reply date: 28.09.2020

Sl. No.	Information Sought	Reply
7.	<p>Is CDSCO-HQ is in receipt of any appeal/application from its staff/officers posted at zonal & sub-zonal offices for consideration of grant of Special Casual Leave (SCL) as per CCS(L) Rules to stranded out of station/home town in national COVID-19 lockdown. If yes Please provide the details.</p> <p>If answer of Q. No. 7 is yes, Please provide the action taken/decision taken in such application.</p>	<p>Not related to this office.</p>
8.	<p>Is CDSCO granted or sanctioned any Special Casual Leave (SCL) as per CCS(L) Rules to any of his regular staff for the days of absence from duty due to national COVID-19 lockdown.</p>	<p>Not applicable to this office.</p>
9.	<p>Please provide the list of employee granted such SCL. As mentioned in Q. No. 9.</p>	<p>Not related to this office.</p>
10.	<p>As per office memorandum no. A.32029/01/2020-D dt. 16-04-2020, Provide list describing how many regular staff were granted leaves as per CCS(L) Rules and and how many contractual staff salary deducted since 20-04-2020.</p>	<p>Not applicable for this institute.</p>
11.		<p>Granting leave as per CCS(L) Rules has not been required as there was no such application, received for granting the same. Salary of contractual Security supervisor, Security guard, Multitasking and Cleaning Staff are not deducted as there was not raised such kind of situation. Salary for other contractual staff is not being disbursed from this office.</p>

➤ **RTI Application No: 4**

Receipt Date: 28.10.2020

Reply date: 19.11.2020

Sl. No.	Information Sought	Reply
Context of the RTI according to the applicant		
<p>UPSC has released the ADVERTISEMENT NO 16 2010 last date for application closure is 16.09.2010 for Vacancy No 10081604128 Eighty one Drugs Inspector in the Central Drugs Standards Control Organization. In this recruitment so many candidates applied for the post of Drugs Inspector with fake 18 months experience. For example S Serapu her Date of Birth is 24.07.1986 and her Age on above notification closing date is 23 years 11 months 23 days only. She is having M Pharm degree. She has already worked as TDA in CDSCO. In Karnataka, Rajasthan and Andhra Pradesh and Telangana, Delhi and other states, Years taken for completion of Master degree in Pharmacy 1 PLUS 4 PLUS 2 total 23 years which is excluding entrance exams, counseling procedures, documents verification, seat allotment etc. She is having 11 months experience only on closing date i.e. 16.09.2010. Technical data associate experience is not eligible for DI recruitment as per Rule 49. Experience was gained on notification 16/2010 closing date shall be 11 months only, (if consider the TDA experience). But as per Drugs and Cosmetics Rules, Rule 49 and notification 18 months experience is mandatory. It is an evident for fake experience candidates were recruited in the ADVERTISEMENT NO. 16 2010.</p>		
<p>1.</p>	<p>Please provide information on</p> <ol style="list-style-type: none"> 1. Exp.Certificate submitted by selected candidates in ADVERTISEMENT NO 16 2010. 2. Photocopy of M.Pharm original certificates of selected candidates in ADVERTISEMENT NO 16 2010. 3. Previous experience certificates selected candidates in ADVERTISEMENT NO 16 2010. 4. TDA appointment orders and TDA reliving order or resignation date, if any candidates of selected candidates in ADVERTISEMENT NO 16 2010. <p>Please do not say that above documents are not comes under purview of RTI. Because of the</p>	<p>No queries are related to this office.</p>

	<p>above fake recruitment, we have lost opportunity for selection of Drugs Inspector in CDSCO. So you are requested to provide the above information in public interest. That batch i.e. 2010 batch is intensively saying that 2015 batch, drugs inspectors are recruited with fake experience of 2015 batch is not eligible for conducting inspections. But our opinion review the all recruited drugs inspectors experience certificates again in public interest. Then, conclude who is fake experience and who are not fake and submitted the evidence documents to me.</p> <p>Please provide the details on active ingredients, Medical devices, Biologicals, Masks, vaccines, cosmetics import details in August, 2020 through CDSCO port offices. Please provide the details on number of Inspections conducted by 2015 batch drugs inspectors in Zonal Offices and other CDSCO offices.</p>	
--	---	--

➤ **RTI Application No: 5**

Receipt Date: 04.12.2020

Reply date: 17.12.2020

Sl. No.	Information Sought	Reply
Context of the RTI according to the applicant		
	<p>As per the judgement of the Himachal Pradesh High Court on 14 August 2020 (CWP No 2572 of 2020, attached), the Regional Drugs Testing Laboratory, Chandigarh, tested bottles of the Coldbest cough syrup from Batch no 5201, manufactured by Himachal Pradesh based Digital Vision on three occasions. The results of these three tests were reported on 5 March 2020, 2 March 2020, and 20 March 2020. On 5 March 2020, RDTL Chandigarh found Coldbest cough syrup, batch 5201, to be of standard quality, but was unable to test for diethylene glycol (DEG), due to inadequate sample size. On 2 March 2020, RDTL, Chandigarh found the cough syrup to be not of standard quality. On 20 March 2020, RDTL Chandigarh found the cough syrup to be not of standard quality.</p>	

<p>1.</p>	<p>Kindly share the following reports with me:</p> <ol style="list-style-type: none"> 1. RDTL Chandigarh report dated 5 March, 2020, in which it found Coldbest cough syrup batch number 5201 to be of standard quality, but was unable to test for DEG due to inadequate sample size. 2. RDTL Chandigarh report dated 20 March, in which it found Coldbest cough syrup batch number 5201 to be adulterated with DEG1. 3. RDTL Chandigarh report dated 2 March 2020, in which it found samples of Coldbest cough syrup, batch number 5201, drawn from Haryana and Jammu and Kashmir, to be contaminated with DEG. 	<p>The information as are desired by the applicant cannot be provided as mentioned bellow;</p> <ul style="list-style-type: none"> • This institute is bound by the fiduciary relationship of trust with the senders of the samples (Drugs, Cosmetics and medical devices), i.e. Drugs Inspectors and Drugs Officers. This office is used to charge the testing fees for samples as per Schedule “B” of Drugs and Cosmetics Act 1940 and Rules 1945 there under. <p>Providing the test reports of samples directly or indirectly to the persons, other than its senders may incur a large financial loss for this institute, as this institute is used to charge fees for testing and submission of test reports of the samples as mentioned earlier.</p> <p>So, the information available to a person in his fiduciary relationship of trust cannot be disclosed under section 8 (1) (e) of RTI Act, 2005.</p> <ul style="list-style-type: none"> • Providing the desired information cannot be used to serve the large public interests. The lists of legal failed samples are regularly being uploaded under the Drug Alert of the CDSCO website, i.e. www.cdsc.gov.in (Notifications → Alert). One of the most common and important purposes of this Drug Alert is to disseminate the information rapidly into a maximum possible extent of common people to alert them about the drugs, cosmetics and medical devices, which are not safe and fit for use. <p>So the information which cannot serve the large public interests cannot be provided taking the risk of financial loss of this Government Institute.</p>
-----------	--	--

		<ul style="list-style-type: none"> Moreover the requested information pertains to 'third party' information, disclosure of which would cause unwarranted invasion of the privacy or can harm the competitive position of the individual pharmaceutical companies/Manufacturers and has no relationship to any public activity or interest. So the requested information is denied u/s 11(1) and 8(1) (j).
--	--	--

➤ **RTI Application No: 6**

Receipt Date: 05.03.2021

Reply date: 09.03.2021

Sl. No.	Information Sought	Reply
(i)	Sir, kindly let me know the updates of recruitment procedure of Junior Scientific Assistant through SSC SELECTION POST PHASE 7(ER11719).	Recruitment of Junior Scientific Assistant, through SSC SELECTION POST PHASE 7(ER11719) is not related with this institute.

➤ **RTI Application No: 7**

Receipt Date: 30.09.2019

Reply date: 21.06.2021

Sl. No.	Information Sought	Reply
1.	<p>1. Post wise sanctioned posts, filled post, vacant post, posts are vacant since how many days in all Central Drugs Testing Laboratories (CDTL).</p> <p>2. Organisation structure of all Central Drug Testing Laboratories.</p> <p>3. List of regular employees along with their designation, pay scales, date of joining in the post of all Central Drug Testing Laboratories.</p>	<p>1. The details are given in Annexure -I.</p> <p>2. Organisational flow Chart of working procedure, given in the link: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/rdtlOrganizationandfunctions2021.pdf is the organization structure.</p> <p>3. The details are given in Annexure -I.</p>

	<p>4. Recruitment Rules of all Central drug Testing Laboratories.</p>	<p>4. The published RR are attached herewith;</p> <p>RR for Director – Annexure-II</p> <p>RR for SSO(Gr-II)/Scientific Officer & SSA– Annexure-III</p> <p>RR for Accountant – Annexure-IV</p> <p>RR for Laboratory Assistant & Laboratory Attendant – Annexure-V</p>
--	---	--

➤ **RTI Application No: 8**

Receipt Date: 10.07.2021

Reply date: 29.07.2021

Sl. No.	Information Sought	Reply
1.	<p>Please refer to your certificate of Test Analysis No. LSD/RDTL/0095/21-22 Dated 20/05/2021 on form 13 in respect of sample No. NZ/SMP/DIL/A/074/2020-21 containing</p> <p>Diphenyl hydrazine HCL Ammonium Chloride Sodium Citrate & Menthol</p> <p>As per the analysis report the sample being patent & Proprietary.</p> <p>Please send me the copy of letter by which the manufacturer was asked to supply STP under Drugs & Cosmetics Act Rule No. 46 (4) and CDSCO guidelines.</p>	<p>1. The referred sample of Test Analysis No. LSD/RDTL/0095/21-22, dated 20/05/2021 on form 13 in respect of sample No. NZ/SMP/DIL/A/074/2020-21 is hereby pertinent to mention that, it does not contain Diphenyl hydrazine HCl, rather it contains Diphenhydramine Hydrochloride IP.</p> <p>2. According to Drugs & Cosmetics Act, Rule No. 46 (4) and CDSCO guidelines, it is not mandatory to ask the manufacturer to supply STP for the Patent & Proprietary samples. Still this laboratory is used to send the letters for STPs in case of Patent & Proprietary samples to its respective senders, i.e. Drugs Inspector wherever it needs to be required, but never send any letter for STP directly to the</p>

		<p>manufacturers.</p> <p>3. The same sample of the same manufacturer of different batch No. was previously received in this laboratory for its testing and analysis. The letter for STP (Standard Testing Procedure and method of Analysis) of this sample was send to its sender and the copy of the letter is annexed herewith as Annexure - I</p> <p>4. The STP (Standard Testing Procedure) for the same from its manufacturer is also received and is available in this office. The Cover letter for the same from its manufacturer is annexed herewith as Annexure –II.</p>
--	--	---

➤ **RTI Application No: 9**

Receipt Date: 02.09.2021

Reply date: 22.09.2021

Sl. No.	Information Sought	Reply
1.	<p>आपके स्वास्थ्य और परिवार कल्याण मंत्रालय (स्वास्थ्य और परिवार कल्याण विभाग), नई दिल्ली ने GSR 103(E) dated 2.2.2017 द्वारा औषधि एवं प्रशाधन सामग्री नियमावली, 1945 में सरकारी विश्लेषक के कर्तव्य के नियम 45(1) में “इन नियमों के अनुसार” शब्दों के बाद ‘इन नियमों के अनुसार नमूने की प्राप्ति के साठ दिन की अवधि के भीतर प्रस्तुत करेगा’ रिपोर्ट देने की अवधि जोड़ी थी। जिसके अनुसार सरकारी विश्लेषकों को साठ दिन की अवधि के भीतर रिपोर्ट देने का वैधानिक प्रावधान किया गया था तथा इनको इस संशोधन के बाद साठ दिन की अवधि के भीतर रिपोर्ट देनी थी परन्तु सरकारी विश्लेषकों द्वारा इस संशोधित प्रावधान की पालना नहीं की</p>	<p>इस कार्यालय में इस प्रकार का कोई अभिलेख नहीं है।</p>

<p>जा रही है, जो साकार की भी जानकारी में है। इस नियम के आखिर में यह भी जोड़ा गया था की जहां निर्दिष्ट अवधि के भीतर नमूने का परीक्षण या विश्लेषण करना संभव नहीं है, वहा सरकारी विश्लेषक इस तरह के परीक्षण में देरी के लिए विशिष्ट कारण बताते हुए सरकार से समय बढ़ाने की अनुमति लेंगे। अंतः कृपया सेंट्रल एवं रीजनल टेस्टिंग लैबोरेट्रीज के सरकारी विश्लेषकों द्वारा इस नोटिफिकेशन के बाद नमूनों की जांच अवधि बढ़ाने के लिए समय समय पर कोई आवेदन किये गए हो और सरकार द्वारा अनुमति दी गए हो तो उसकी प्रतियां उपलब्ध कराने का कष्ट करावें। इसके अतिरिक्त क्या यह सरकार के संज्ञान में नहीं है की इस नोटिफिकेशन के बाद सरकारी विश्लेषको द्वारा समय पर रिपोर्ट नहीं देने से 2.2.2017 के बाद जारी रिपोर्ट्स की वैधानिकता पर प्रभाव पड़ेगा ?</p>	
---	--

➤ **RTI Application No: 10**

Receipt Date: 15.09.2021

Reply date: 22.09.2021

Sl. No.	Information Sought	Reply
1.	<p>Please provide me the following details of all the current ongoing Recruitment process at CDSCO Including its Zones, Subzones, Port Offices and Laboratories.</p> <ol style="list-style-type: none"> 1. Publication date of the notification. 2. Last date of receiving Applications. 3. Number of Applications received with category wise breakup. 4. Name of the post with no. of vacancies for which applications are sought 5. Current status. 6. Detailed timeline in which the recruitment process is scheduled to be completed. 7. Detailed process by which aforesaid vacancies will 	<p>Currently, the recruitment process for the post of one JSA (Junior Scientific Assistant) is going on through Staff Selection Comission (North West Region). The claimed information cannot be provided according to the letter of SSC to this office. The copy of office letter of SSC is being attached herewith.</p>

	<p>be filled.</p> <p>8. Any other important information about the recruitment process deemed necessary to be shared.</p> <p>9. Kindly attach a copy of all the office orders, memos, notice, e-mail and letters sent and received with respect to the aforementioned recruitment process.</p>	
--	---	--

➤ **RTI Application No: 11**

Receipt Date: 12.10.2021

Reply date: 12.10.2021

Sl. No.	Information Sought	Reply
(i)	<p>The PIO has so far not provided me the information under the RTI Act 2005, therefore, as per Section 7(2) it is deemed refusal of the information. I am entitled for the information sought under the RTI Act. SPIO neither communicated his decision nor supplied information within stipulated time limit of 30 days. Therefore, direct the PIO to send information as sought vide my RTI Application free of cost.</p>	<ul style="list-style-type: none"> • Your RTI application No. CDSCO/R/T/21/00695, dated 02.08.2021, was received in this office on 02.09.2021 from the Assistant Drug Controller (India) & CPIO, Directorate General of Health Services, Central Drugs Standard Control Organisation, FDA Bhawan, Kotla Road, New Delhi under Section 6(3) of RTI Act, 2005 vide the letter no. Z-28020/1050/2021-DC, dated 01/09/2021. • The reply from CPIO of this institute for the same has been sent to you through registered post on 22/09/2021. • The photocopy of the same has been again sent to you for your ready references.

➤ **RTI Application No: 12**

Receipt Date: 17.11.2021

Reply date: 25.11.2021

Sl. No.	Information Sought	Reply
(i)	<p>I may kindly be provided the following information (Certified copies of the document, records and letters).</p> <ol style="list-style-type: none"> 1. Copy of the Letter/O.M on or after dated 01/07/2017 regarding payment of HPCA/PCA to the all the eligible post at Central Drugs Laboratory, Central Drugs Testing Laboratory, Medical Stores Organisation, Central Health Education Bureau, Rural Health Training Centre, International Health, PHO, APHO, LPHU, GHSA, NOTTO, RET, MOFRS, CBHI & LBQ (Letter like NCDC No. A.27023/01/2017-Estt. Dated 16/10/2019 & NVBDCP No. 1-105/2019-Admn, dated 15/11/2019). 2. List of Post/Designation who all are eligible to receiving HPCA/PCA. 3. List of Post/Designation who all are eligible to receiving HPCA/PCA but not received HPCA/PCA during the 6th CPC (Central Pay Comission—ie Pay Rule 2008). 4. The copy of Note Sheet of the file Letter/File No. A-26024/02/2019-RD dated 07/01/2021 (Pages 40 to last Pages) or A-26023/02/2019-RD Dated 07/01/2021 (Pages 40 to last Pages) regarding PCA/HPCA. 	<ol style="list-style-type: none"> 1. No such Letter/O.M on or after dated 01/07/2017 regarding payment of HPCA/PCA to the all the eligible post at this office is available. 2. No such list of Post / Designation who all are eligible to receiving HPCA/PCA is available in this office. 3. No such list of Post/Designation who all are eligible to receiving HPCA/PCA but not received HPCA/PCA during the 6th CPC (Central Pay Comission—ie Pay Rule 2008) is available in this office. 4. No such copy of Note Sheet of the file Letter/File No. A-26024/02/2019-RD dated 07/01/2021 (Pages 40 to last Pages) or A-26023/02/2019-RD Dated 07/01/2021 (Pages 40 to last Pages) regarding PCA/HPCA is available in this office.

➤ **RTI Application No: 13**

Receipt Date: 17.01.2022

Reply date: 04.02.2022

Sl. No.	Information Sought	Reply																																																														
1.	<p>Please provide the following information in public interest:</p> <p>Number of following samples received as Form-18, survey, state or court case send by drug inspector, DDC or court and tested under Drug and cosmetics Act 1940 laboratories: Central Drugs Laboratory, Kolkata; Central Drugs Testing Laboratory, Chandigarh from April 2020 to 01.12.2021 in any readily available formats in their respective offices.</p> <ol style="list-style-type: none"> 1. Remdesivir injection 2. Favipiravir tablets 3. Tocilizumab injection 4. Amphotericin B, Posoconazole, Isavuconazole <p>Also provide information out of above received samples how many declared as not of standard quality samples by respective laboratories.</p>	<p>The claimed information is provided as below:</p> <table border="1" data-bbox="670 478 1498 1293"> <thead> <tr> <th data-bbox="670 478 743 779">Sl. No.</th> <th data-bbox="743 478 938 779">Name of Drugs</th> <th colspan="5" data-bbox="938 478 1498 527">No. of Received Samples</th> </tr> <tr> <td></td> <td></td> <th data-bbox="938 527 1040 779">Form-18</th> <th data-bbox="1040 527 1149 779">Survey</th> <th data-bbox="1149 527 1247 779">State / Court case</th> <th data-bbox="1247 527 1360 779">No. of Sample tested</th> <th data-bbox="1360 527 1498 779">No. of sample Not of Standard Quality</th> </tr> </thead> <tbody> <tr> <td data-bbox="670 779 743 884">1</td> <td data-bbox="743 779 938 884">Remdesivir Injection</td> <td data-bbox="938 779 1040 884">04</td> <td data-bbox="1040 779 1149 884">00</td> <td data-bbox="1149 779 1247 884">00</td> <td data-bbox="1247 779 1360 884">04</td> <td data-bbox="1360 779 1498 884">02</td> </tr> <tr> <td data-bbox="670 884 743 989">2</td> <td data-bbox="743 884 938 989">Favipiravir tablets</td> <td data-bbox="938 884 1040 989">00</td> <td data-bbox="1040 884 1149 989">46</td> <td data-bbox="1149 884 1247 989">00</td> <td data-bbox="1247 884 1360 989">46</td> <td data-bbox="1360 884 1498 989">00</td> </tr> <tr> <td data-bbox="670 989 743 1094">3</td> <td data-bbox="743 989 938 1094">Tocilizumab injection</td> <td data-bbox="938 989 1040 1094">00</td> <td data-bbox="1040 989 1149 1094">00</td> <td data-bbox="1149 989 1247 1094">00</td> <td data-bbox="1247 989 1360 1094">00</td> <td data-bbox="1360 989 1498 1094">00</td> </tr> <tr> <td data-bbox="670 1094 743 1199">4</td> <td data-bbox="743 1094 938 1199">Amphotericin B</td> <td data-bbox="938 1094 1040 1199">04</td> <td data-bbox="1040 1094 1149 1199">01</td> <td data-bbox="1149 1094 1247 1199">00</td> <td data-bbox="1247 1094 1360 1199">05</td> <td data-bbox="1360 1094 1498 1199">03</td> </tr> <tr> <td data-bbox="670 1199 743 1293">5</td> <td data-bbox="743 1199 938 1293">Posoconazole</td> <td data-bbox="938 1199 1040 1293">00</td> <td data-bbox="1040 1199 1149 1293">00</td> <td data-bbox="1149 1199 1247 1293">00</td> <td data-bbox="1247 1199 1360 1293">00</td> <td data-bbox="1360 1199 1498 1293">00</td> </tr> <tr> <td data-bbox="670 1293 743 1398">6</td> <td data-bbox="743 1293 938 1398">Isavuconazole</td> <td data-bbox="938 1293 1040 1398">00</td> <td data-bbox="1040 1293 1149 1398">00</td> <td data-bbox="1149 1293 1247 1398">00</td> <td data-bbox="1247 1293 1360 1398">00</td> <td data-bbox="1360 1293 1498 1398">00</td> </tr> </tbody> </table>							Sl. No.	Name of Drugs	No. of Received Samples							Form-18	Survey	State / Court case	No. of Sample tested	No. of sample Not of Standard Quality	1	Remdesivir Injection	04	00	00	04	02	2	Favipiravir tablets	00	46	00	46	00	3	Tocilizumab injection	00	00	00	00	00	4	Amphotericin B	04	01	00	05	03	5	Posoconazole	00	00	00	00	00	6	Isavuconazole	00	00	00	00	00
Sl. No.	Name of Drugs	No. of Received Samples																																																														
		Form-18	Survey	State / Court case	No. of Sample tested	No. of sample Not of Standard Quality																																																										
1	Remdesivir Injection	04	00	00	04	02																																																										
2	Favipiravir tablets	00	46	00	46	00																																																										
3	Tocilizumab injection	00	00	00	00	00																																																										
4	Amphotericin B	04	01	00	05	03																																																										
5	Posoconazole	00	00	00	00	00																																																										
6	Isavuconazole	00	00	00	00	00																																																										

➤ **RTI Application No: 14**

Receipt Date: 27.01.2022

Reply date: 14.02.2022

Sl. No.	Information Sought	Reply
1.	<p>According Right to information Act 2005 please furnish regarding following details regarding vaccancies in esteemed CDSCO and CDTL all over the country</p> <ol style="list-style-type: none"> 1. Details of establishment and sanctioned strength of each Zonal, Sub zonal, Port Offices of CDSCO and Laboratories (including Mini Drugs Testing Laboratories (Air/Sea Port Labs) and Mobile Testing Laboratories) under CDSCO, DGHS, Min. of Health and Family Welfare in the following format 2. Name, Designation, Educational Qualification, Date(s) of joining, relevant testing (Drugs/Cosmetics) experience of Director (or) Director-in-charge (or) Head of the laboratory who is looking presently all administrative and technical matters of each laboratory under CDSCO. 3. Provide the details of latest approved Recruitment Rules for the sanctioned posts of Group A & B under CDSCO Offices and Laboratories of 	<p>The claimed information is provided as below:</p> <p>Name: Dr. R. A. Singh Designation: Director Educational Qualification: M. Sc, PhD (Chemistry). F.I.C., C.C. Date of joining: 03/08/2009 Relevant testing (Drugs/Cosmetics) experience: More than 12 Years.</p> <p>Ditrector is the Head of the laboratory and is looking presently all administrative and technical matters of this laboratory under CDSCO. There is no Director-in-charge in this laboratory.</p> <p>RR of Director: Attacheed as Annexure 1 RR of Senior Scientific Officer (Gr-II) and Senior Scientific Assistant: Attached as</p>

	<p>CDSCO, DGHS, MoHFW.</p> <p>4. Name, Designation, Educational Qualification and Relevant Experience (as per Drugs and Cosmetics Act 1940) of Government Analysts of each laboratory under CDSCO.</p> <p>5. Total number of permanent staff of each laboratory who has not received promotion during his 15 years of service under Central Drugs Laboratories of CDSCO, DGHS, MoHFW.</p> <p>6. The details of each permanent Staff of the Laboratory under CDSCO in the following format. S.No Name and Designation Educational Qualification Date of Joining in Service Nature of recruitment to the present post (Direct/Promotion) with Date of Joining Number of promotions including MACP (if any) during total service.</p>	<p>Annexure 2</p> <p>RR of JSA: Attached as Annexure 3</p> <p>RR of Accountant: Attached as Annexure 4</p> <p>RR of Laboratory Assistant and Laboratory Attendant: Attached as Annexure 5</p> <p>List of Government Analyst:</p> <p>1. Dr. R. A. Singh, Designation - Director, Other Details: are as mentioned above.</p> <p>2. Sh. Hitesh Kumar Khare, Designation - Senior Scientific Officer Gr-II, Qualification - MSc. Biochemistry, Experience - 14 years.</p> <p>3. Dr. Debasis maiti, Designation - Senior Scientific Officer Gr-II. Qualification - MSc. Microbiology, MBA, Ph.D. Biochemistry, Experience - 5 years.</p> <p>No such case is still arrived in this laboratory.</p> <p>Attached as Annexure 6</p>
--	--	--

	Total years of Service
--	------------------------

➤ **RTI Application No: 15**

Receipt Date: 17.02.2022

Reply date: 25.02.2022

Sl. No.	Information Sought	Reply										
(i)	<p>Sir,</p> <p>You are requested to treat this letter as an application under Section 6 of the Right to Information Act and respond accordingly to the following queries:</p> <p>7. Please provide copies of the laboratory's budget statements since 1st April, 2016.</p> <p>8. How many HPLC (high performance liquid chromatography) machines are installed in your laboratory? How old are these machines?</p> <p>9. What kind of instrumentation does your lab use to test for dissolution? How many such pieces of instrumentation does your lab have?</p> <p>10. How many drug samples has your laboratory tested since 1st January, 2016?</p> <p>11. How many of the above samples failed quality testing?</p> <p>12. How many reference standards and impurity standards have been procured by</p>	<p>The claimed information is provided as below:</p> <p>Details has been attached as Annexure-1</p> <p>Details has been attached as Annexure-2</p> <p>Details has been attached as Annexure-3</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">Time Period</th> <th style="width: 15%;">Total number of samples tested</th> <th style="width: 15%;">Number of samples declared as not standard quality</th> <th style="width: 15%;"></th> <th style="width: 15%;"></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">01.01.2016 to 22.02.2022</td> <td style="text-align: center;">Legal Samples 10223</td> <td style="text-align: center;">Survey samples 9593</td> <td style="text-align: center;">Legal Samples 604</td> <td style="text-align: center;">Survey samples 140</td> </tr> </tbody> </table> <p>320 Reference Standards and 38 Impurities have been procured from Indian Pharmacopeia</p>	Time Period	Total number of samples tested	Number of samples declared as not standard quality			01.01.2016 to 22.02.2022	Legal Samples 10223	Survey samples 9593	Legal Samples 604	Survey samples 140
Time Period	Total number of samples tested	Number of samples declared as not standard quality										
01.01.2016 to 22.02.2022	Legal Samples 10223	Survey samples 9593	Legal Samples 604	Survey samples 140								

	<p>your laboratory from the Indian Pharmacopoeia Commission since 1st January 2016?</p> <p>13. Has your laboratory faced delays in procuring reference standards and impurity standards from the Indian Pharmacopoeia Commission? If also, please explain the duration of the delays and how these delays affected your testing capacity.</p> <p>14. How does your lab test for impurities in the samples you are sent to test for drug quality?</p> <p>15. Do you request Reference Standards or Impurity Standards from the manufacturer of the drug when you test their product? If so, how many times has that happened since 1st January 2016?</p>	<p>Commission since 1st January 2016 to 22.02.2022.</p> <p>No such kind of instance has been faced or documented.</p> <p>As per Drugs and Cosmetics Act 1940 and rules there under.</p> <p>This laboratory used to request the respective Drug Inspectors of the samples for Reference Standards or Impurity Standards in absence of the same in this laboratory but never send any request to the manufacturer.</p>
--	---	--

Annexure 2:

Details of HPLC								
SR. No.	NAME OF INSTRUMENT	MAKE	MODEL	INSTRUMENT ID NO.	INSTALLATION DATE	INSTALLATION TIME PERIOD		
						YEARS	MONTHS	DAYS
1.	High Performance Liquid Chromatography	Agilent Technologies	Agilent 1200 Series	RDTL-INS-39	02.08.11	10	06	19
2.	High Performance Liquid Chromatography-PDA	Perkin Elmer	Flexar	RDTL-INS-77	15.04.15	06	10	06
3.	High Performance Liquid Chromatography	Perkin Elmer	Flexar	RDTL-INS-78	12.05.15	06	09	09
4.	High Performance Liquid Chromatography	Perkin Elmer	Flexar	RDTL-INS-80	20.05.15	06	09	01
5.	High Performance Liquid Chromatography	Perkin Elmer	Flexar	RDTL-INS-82	22.05.15	06	08	30
6.	High Performance Liquid Chromatography	Perkin Elmer	Flexar	RDTL-INS-79	23.05.15	06	08	29
7.	High Performance Liquid Chromatography	Perkin Elmer	Flexar	RDTL-INS-81	25.05.15	06	08	27
8.	High Performance Liquid Chromatography	Perkin Elmer	Flexar	RDTL-INS-83	25.05.15	06	08	27
9.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-124	01.05.18	03	09	20
10.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-132	17.12.18	03	02	04
11.	High	Thermo	Thermo	RDTL-INS-	17.12.18	03	02	04

	Performance Liquid Chromatography	Fisher	Dionex Ultimate 3000	133				
12.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-134	17.12.18	03	02	04
13.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-135	17.12.18	03	02	04
14.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-136	17.12.18	03	02	04
15.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-137	17.12.18	03	02	04
16.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-131	17.12.18	03	02	04
17.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-129	21.12.18	03	02	00
18.	High Performance Liquid Chromatography	Thermo Fisher	Thermo Dionex Ultimate 3000	RDTL-INS-130	21.12.18	03	02	00
19.	High Performance Liquid Chromatography-ELSD	Agilent Technologies	AGILENT 1260	RDTL-INS-145	30.08.19	02	05	22

Annexure 3:

INSTRUMENTS USED TO TEST FOR DISSOLUTION								
S N	NAME OF INSTRUMENT	MAKE	MODEL	INSTRUMENT ID NO.	INSTALLATION DATE	INSTALLATION TIME PERIOD		
						YEARS	MONTHS	DAYS
1.	DISSOLUTION TEST APPARATUS (MANUAL)	LAB INDIA	DS8000	RDTL-INS-41	08.11.11	10	03	13
2.	DISSOLUTION TEST APPARATUS (MANUAL)	LAB INDIA	DS8000	RDTL-INS-56	29.07.13	08	06	23
3.	DISSOLUTION TEST APPARATUS (MANUAL)	LAB INDIA	DS8000	RDTL-INS-88	28.07.15	06	06	24
4.	DISSOLUTION TEST APPARATUS (AUTO SAMPLER)	LAB INDIA	DS8000+	RDTL-INS-97	29.10.15	06	03	23
5.	DISSOLUTION TEST APPARATUS (AUTO SAMPLER)	LAB INDIA	DS8000+	RDTL-INS-113	29.05.17	04	08	23
6.	DISSOLUTION MEDIA PREPARATION SYSTEM	TELEDYNE HENSON RESEARCH	MEDIA MATE PLUS-40	RDTL-INS- 125	06.06.18	03	08	15

➤ **RTI Application No: 16**

Receipt Date: 21.03.2022

Reply date: 24.03.2022

Sl. No.	Information Sought	Reply
1.	Respected Sir, With reference to above subject you are requested to give Record Inspection of the concern file of your letter No CDL/2021/5209 Dated 14-09-2021 under R.T.I. Act 2005.	The mentioned letter no. (CDL/2021/5209 Dated 14-09-2021) does not pertain to this laboratory.

➤ **RTI Application No: 17**

Receipt Date: 21.03.2022

Reply date: 25.03.2022

Sl. No.	Information Sought	Reply
1.	Sir, Kindly provide the certified copy of Recruitment Rules of all the Administrative Cadre in the Organization.	Only Director and Accountant posts in the Administrative Cadre are existing in this laboratory. RRs of these posts are provided as claimed.

2020-22		
Sl. No.	Total No. of RTI Received	Total No. of RTI Replied
1.	17	18